Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GenomeDx Biosciences Corp
The primary and secondary objectives will be assessed in retrospectively selected prostate cancer patients treated with radical prostatectomy with one or more adverse pathological features (APFs)
Age
Any age
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Criteria (Participant enrollment)
1. Practicing board-certified urologic surgeons
2. Performing at least 40 radical prostate surgeries annually
Criteria (Case selection)
Patient cases eligible for this study were treated with radical prostatectomy and have one or more adverse pathological features present defined as:
Pathological Gleason score \>= 8 or Gleason score 7 with primary pattern 4; Pathological stage T3A (= Extraprostatic extension) or T3B (=Seminal vesicle invasion); Positive surgical margins Gleason grade upgrade from biopsy to surgery
You may not be if
Metastatic disease (M+) prior to surgery Received any neo-adjuvant prostate cancer treatment with radical prostatectomy (radiation, hormone, chemotherapy)
Clareo Health | Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations
